CSCI Research Brief

Cannabinoid Therapy In Epilepsy

Billakota S, Devinsky O, Marsh E. Cannabinoid therapy in epilepsy. Current Opinion in Neurology. 2019;32(2):220-226. doi:10.1097/wco.0000000000000660

This review study was conducted to take a look at the role of cannabidiol (CBD) in the treatment of epilepsy. 

Cannabidiol (CBD) is the type of cannabinoid therapy used to treat certain types of rare and severe pediatric onset epilepsy.

Cannabinoid Therapy In Epilepsy: Study Findings

Phase III randomized controlled trials have shown that Epidiolex is safe and effective when used as a prescription medication for pediatric onset severe epilepsies. Epidiolex (cannabidiol) is an antiepileptic drug available in an oral solution Epidiolex is for the treatment of specific types of seizures in Lennox-Gastaut syndrome or Dravet syndrome; it can be given to those aged two and older. Epidiolex contains over 99% CBD and less than 0.10% Delta-9-tetrahydrocannabinol (THC). It is the first medication of its kind to be approved by the U.S. Food and Drug Administration (FDA).

Summary 

Research that discovered the endocannabinoid system (ECS) and how cannabinoids such as CBD and THC work, Epidiolex is the first medically approved CBD treatment deemed safe and effective for the treatment of epilepsy; although this represents an important milestone, the use of cannabis derived products, such as CBD, to treat other medical conditions, including other forms of epilepsy, is yet to be determined.
Link to the article:  https://doi.org/10.1097/wco.0000000000000660

General Disclaimer

Center for Scientific Cannabinoid Information (CSCI) has placed information, including links to other websites or content belonging to or originating from third parties, on this website as a service to the general public and for general informational and educational purposes only.  The information on this website is not intended to substitute particularized advice of specialists or qualified professionals.  No content on this website should ever be used as a substitute for direct advice from appropriate professionals or qualified specialists.  This website could include inaccuracies or typographical errors.  The materials on this website do not constitute medical advice, do not necessarily reflect the opinions of CSCI or any of its employees, agents, affiliates, or subsidiaries, and are not guaranteed to be correct, complete, or up‐to‐date.  The publications, articles, and information on this website are provided as is without warranty of any kind, either express or implied, regarding accuracy, adequacy, validity, reliability, availability, or completeness, and CSCI does not warrant, endorse, guarantee, or assume responsibility for the accuracy or reliability of any information included on this website from third-party websites linked through this website.  UNDER NO CIRCUMSTANCE SHALL CSCI HAVE ANY LIABILITY TO YOU FOR ANY LOSS OR DAMAGE OF ANY KIND INCURRED AS A RESULT OF THE USE OF THE INFORMATION CONTAINED ON THIS WEBSITE OR RELIANCE ON ANY SUCH INFORMATION PROVIDED ON THIS WEBSITE. YOUR USE OF THIS WEBSITE AND YOUR RELIANCE ON ANY INFORMATION ON THIS WEBSITE IS SOLELY AT YOUR OWN RISK.

You cannot copy content of this page